AroCell develops standardized modern blood samples to support the prognosis and follow-up of cancer patients.
AroCell’s new technology is based on patented methods for measuring protein concentrations of thymidine kinase 1 (TK1) in a blood sample. The TK 210 ELISA test provides valuable information, primarily on the condition of cancer patients. This can help clinicians optimize treatment strategies and estimate the risk of recurrence of tumor disease while monitoring the disease.
STATUS: Exit
